Alliances
Roche’s Flatiron Health and the U.S. Food and Drug Administration’s Information Exchange and Data Transformation (INFORMED) Program expanded a two-year-old collaboration agreement.
Months after Akcea Therapeutics unveiled positive mid-stage data that showed its therapy reduced elevated levels of lipoprotein(a) in patients with cardiovascular disease (CVD), Swiss pharma giant Novartis exercised its option to take license the therapy and take it through late-stage studies.
Voyager Therapeutics struck a deal with Illinois-based AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease.
3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets selected by Boehringer Ingelheim.
Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.
Waltham, Mass.-based Morphic Therapeutic and Janssen Biotech, a division of Johnson & Johnson, entered into a collaborative deal to develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
Evotec and helmholtz aim to jointly develop cystobactamid derivatives into a new class of broad spectrum antiobiotics targeting high-priority pathogens
Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
ADL Bionatur Solutions, by partnering with Nutricion Center NC, opens up big opportunities in the Spanish pharmacy sector: reaching over 2,000 direct sales points; and 20,000 pharmacies
When your back hurts, your whole body hurts. This morning, Pfizer and Eli Lilly reported positive results from its Phase III back pain treatment tanezumab.
PRESS RELEASES